FindMyKOL
Clinical trialNCT04654975UnknownObservational

Metachronic Brain Metastases After Esophagectomy for Esophageal Cancer (METABREC)

SponsorUniversitaire Ziekenhuizen KU LeuvenEnrollment10,000Brain MetastasesEsophageal NeoplasmsEsophagectomy
View the registry record on ClinicalTrials.gov

Summary

The lay summary the sponsor registered on ClinicalTrials.gov.

Esophagectomy is the cornerstone of the curative treatment of esophageal carcinoma. Despite this treatment, patients can suffer from locoregional or distant metastatic disease and only a very selected group of patients can be cured: mostly those with recurrence in one single organ. Brain metastases are rare after esophagectomy for cancer, but they have a serious impact on survival. Agressive treatment is often moren difficult for brain metastases compared to other metastases and some risk factors have been identified earlier. There is an impression that the incidence of brain metastases in esophageal cancer patients has increased since the introduction of neoadjuvant treatment schemes. However, this is not clear yet. A potential explanation could be that chemotherapy disturbs the blood-brain-barrier, hereby facilitating the migration of tumor cells to the brain. The purpose of this study is to retrospectively analyze the incidence and potential risk factors of brain metastases in patients who underwent esophagectomy for esophageal cancer. Patients treated between 2000 and 2019 will be included and outcome parameters are Odds Ratio for brain metastases (comparison between primary surgery and neoadjuvant treatment followed by surgery), time to recurrence and risk factors, number and characteristics of the brain metastases.

Investigators

The overall officials registered on this study. Names that resolve to a FindMyKOL profile link to it; the rest are shown as registered.

A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.

Sites

8 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.

Belgium
  • Universitair Ziekenhuis Gent

    Ghent, Belgium

    Elke Van Daele
    Not, yet, recruiting
France
  • Centre Hospitalier Régional Universitaire de Lille

    Lille, France

    Guillaume Piessen, PhD
    Not, yet, recruiting
Ireland
Netherlands
  • Amsterdam Umc

    Amsterdam, Netherlands

    Mark Van Berge Henegouwen, PhD
    Recruiting
  • Zuyderland Mc

    Heerlen, Netherlands

    Meindert Sosef, PhD
    Not, yet, recruiting
  • Erasmus Mc

    Rotterdam, Netherlands

    Bas Wijnhoven, PhD
    Not, yet, recruiting
Sweden
  • Karolinska Institutet

    Stockholm, Sweden

    Magnus Nilsson, PhD
    Recruiting
United States
  • Md Anderson Cancer Center

    Houston, Texas, United States

    Wayne Hofstetter
    Not, yet, recruiting

Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.

Drugs studied

No drug or biological interventions are in our data for this study. It may test a procedure, device or behavioral intervention, or the intervention list isn't in our current snapshot. See the registry record ↗. Why? →

Registration & key dates

Registry attributes as recorded on the ClinicalTrials.gov study record.

Start
2 Jun 2020
Primary completion
31 Mar 2025
Completion
31 Mar 2025
Last update posted
3 Jul 2024
Registered enrollment
10,000
Registry id
NCT04654975

Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 11 Nov 2026. Registry facts are shown as registered by the study sponsor; FindMyKOL does not interpret them.